Small Molecule Antagonists of the MDM2 Oncoprotein as Anticancer Agents

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|5|1|57-68

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.5, Iss.1, 2005-02, pp. : 57-68

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists

By  

Current Pharmaceutical Design, Vol. 17, Iss. 6, 2011-02 ,pp. : 560-568

Bentham Science Publishers

Access to resources Recommend Favorite

Small molecule v integrin antagonists: novel anticancer agents

By Kerr J.S.   Slee A.M.   Mousa S.A.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 6, 2000-06 ,pp. : 1271-1279

Informa Healthcare

Access to resources Recommend Favorite

Small Molecule Inhibitors of the p53-MDM2

By  

Current Medicinal Chemistry, Vol. 15, Iss. 17, 2008-07 ,pp. : 1720-1730

Bentham Science Publishers

Access to resources Recommend Favorite

p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents

By  

Current Cancer Drug Targets, Vol. 18, Iss. 8, 2018-10 ,pp. : 749-772

Bentham Science Publishers

Access to resources Recommend Favorite

Small Molecule Antagonists of the CXCR2 and CXCR1 Chemokine Receptors as Therapeutic Agents for the Treatment of Inflammatory Diseases

By  

Current Topics in Medicinal Chemistry, Vol. 6, Iss. 13, 2006-01 ,pp. : 1345-1352

Bentham Science Publishers

Access to resources Recommend Favorite